Home
About Us
About Us

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
News
R&D
R&D

Primarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases.
Investor Relations
Investor Relations

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Our Businesses
- NL-PHARM
- Hounland
Our Businesses

Owns Beijing Northland Biopharmaceutical Co., Ltd. and Beijing Huons Pharmaceutical Co., Ltd., which are engaged in bioengineering drugs and ophthalmic products, respectively.

Language

中文简体

English

Home

Corporate Governance

Directors and Management Team

Xu Songshan

President,CEO

Xu Songshan

Senior engineer, associate chief physician, licensed pharmacist, part-time professor at Beijing Normal University, member of the CPPCC Committee of Haidian District, Beijing, and member of the Committee of the Beijing Federation of Overseas Chinese.

View details

Nie Liya

Director, Executive Vice President

Nie Liya

Professor-level Senior Engineer. He holds a Bachelor's degree in Biochemistry from Lanzhou University, a Ph.D. in Biomolecular Engineering from Tianjin University, and completed postdoctoral research at the Academy of Military Medical Sciences.

View details

Han Chengquan

Director, Vice President

Han Chengquan

Master of Molecular Human Genetics from Korea University.He is proficient in Korean and Japanese, and has over 15 years of experience in pharmaceutical clinical research. Currently serving as Vice President of Northland, he oversees clinical, medical, and regulatory affairs, while also acting as General Manager of the Shanghai branch.

View details

Gao Jie

Director ,CFO, Board Secretary

Gao Jie

Certified Public Accountant (CPA) and Senior Accountant. She previously worked at Beijing Yongtuo Accounting Firm, ZhongShen International Accounting Firm, China Huanqiu Contracting & Engineering Corporation, where she held positions including Senior Manager, Partner and Financial Controller for a state-owned mega enterprise. With over 20 years of industry and capital operation experience, she joined Northland in 2016 and currently serves as Director, CFO and Board Secretary .

View details

Xu Rishan

Company director

Xu Rishan

Senior Engineer, Bachelor’s degree in Physics from Zhejiang University, and Master’s degree in Radio Physics and Electronics from Soochow University.

View details

Ren Zili

Independent director

Ren Zili

Doctor, Professor at Beijing University of Aeronautics and Astronautics, and Doctoral Supervisor.

View details

Chen Lei

Company director

Chen Lei

Master’s degree in Materials Science from Tsinghua University, founding partner of Wuhan Donghu Qicheng Investment, specializing in investments in the biopharmaceutical, healthcare, and new materials sectors. Possesses extensive investment experience and industry connections.

View details

Xu Hui

Independent director

Xu Hui

Bachelor’s degree from Peking University, Certified Public Accountant, and National Registered Internal Auditor.

View details

Wang Yingdian

Independent director

Wang Yingdian

Doctor, Professor at the School of Life Sciences, Beijing Normal University, and Doctoral Supervisor.

View details

Basic Information

Full company name	Beijing Northland Biotechnology Co., Ltd. (stock code: 920047)
English name	Beijing Northland Biotech Co., Ltd.
Legal representative	Xu Songshan
Company Secretary	Gao Jie
Registered capital	CNY ¥274,271,974
Date of Establishment	2004/6/3
Listing date	2021/11/15 (Beijing Stock Exchange)
Postal code	100085
Company phone	010-82890893
Company Fax	010-82890892
Company website	http://www.northland-bio.com/
Sponsoring Broker	Zhong Tai Securities Co., Ltd.
Contact email	lilihua@northland-bio.com

Investor Contact

Tel：

+86 010 82890893

Fax：

+86 010 82890892

Email：

lilihua@northland-bio.com

Address：

No. 5, Kaituo Road, Shangdi, Haidian District, Beijing, Building A406, Zhongguancun Biomedical Park

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

ADR information: Click to Download

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

Web site

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license